This week in drug discovery (10-14 June) 

News round-up for 10-14 June by DDW Senior Digital Content Editor Diana Spencer.

With a lead story on the restoration of congenital hearing loss following gene therapy, the news highlights selection this week focuses on cell and gene therapies (CGT) and genetics, particularly some key progress in relation to CAR-T therapies.

The top stories:

Gene therapy restores hearing in both ears

Five children who were born with congenital hearing loss can hear in both ears after taking part in a gene therapy trial at Fudan University in Shanghai, China.

EU relaxes safety monitoring of CAR-T therapies

The European Medicines Agency has approved a Type II variation to the Summary of Product Characteristics (SmPC) for Kite’s chimeric antigen receptor (CAR)-T cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel).

Researchers discover genetic cause of bowel diseases

Researchers have discovered a new biological pathway in inflammatory bowel disease (IBD) and related conditions that can be targeted using existing drugs.

Companies partner on TCR T-cell therapy for head & neck cancer

Adaptimmune Therapeutics and Galapagos have entered into a clinical collaboration agreement to develop Adaptimmune’s TCR T-cell therapy for head and neck cancer and other potential solid tumours.

CAR-T therapy successfully targets advanced prostate cancer

A team of investigators at City of Hope in the US funded by the Prostate Cancer Foundation (PCF) reports that patients with advanced prostate cancer can be safely treated with chimeric antigen receptor (CAR)-T cell therapy.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free